• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.
By BRET JENSEN
Jun 28, 2017 | 03:30 PM EDT
Stocks quotes in this article: OMER, PTLA, PIRS, AZN, ADMP

With biotech underperforming the overall market by a wide swath over the past two years and still down nearly 25% from its previous peak in July 2015, I believe the sector could outperform the larger market through the end of the year.

A late-day selloff Tuesday saw the main biotech indices pull back nearly 3% when all was said and done yesterday. However, some profit-taking was inevitable given the sector had a 10% surge last week, especially in high-flying names such as Omeros Corporation (OMER) , which had shot up 75% in a blink of an eye.

As we look to close out the first half of 2017 on a winning note this week, here are three attractive small-cap sector names.

Portola Pharmaceuticals Inc. (PTLA) had a big rise last week as the FDA approved its compound Betrixaban, an extended-duration anticoagulant for the prevention of venous thromboembolism (VTE) in hospitalized at-risk adult patients. The San Francisco-based company is also expected to resubmit a Biologic License Application (BLA) for its compound AndexXa.

AndexXa is the first universal antidote to the new anticoagulants that have come out in recent years, including Eliquis and Xarelto. Around 1-4% of individuals who use these anticoagulants will have adverse side effects that require hospitalization or a trip to the ER -- some 90,000 incidents a year. Once approved, every hospital and ER will have to have a supply of AndexXa on hand.

Portola would also make a logical buyout target for a larger player with an established sales force. Several analyst firms have hiked price targets on Portola into the $70s this week.

Going smaller, Pieris Pharmaceuticals Inc. (PIRS) has had a nice run over the past couple of months, but there appears to be more upside to this one-time "Busted IPO." Pieris is pioneering the use of small-sized proteins called Anticalins. These proteins have high specificity to their targets and demonstrate tight binding and effective biological activities at their targets. They could prove effective in a variety of settings, including immuno-oncology, oncology, anemia, asthma and infectious diseases.

Pieris has a diverse pipeline and signed a large collaboration deal with drug giant AstraZeneca plc (AZN) . This deal provided an over $50 million upfront payment and Pieris could receive up to an additional $2.1 billion in development-dependent and commercial milestones along with tiered royalties on any approved products -- pretty significant given the company has a current market capitalization of just $200 million.

Lastly, the FDA has finally approved Adamis Pharmaceuticals Corp.'s (ADMP) generic version of the EpiPen in mid-June. And I expect the company to sign a distribution deal with a larger drug player by fall to market this device.

Adamis has a market cap of less than $150 million so even a 5% to 10% market share in the over $1 billion EpiPen market could trigger significant capital appreciation for the stock.

Editor's Note: This article contains one or more stocks with a market cap between $100 million and $2 billion. Such small-cap stocks tend to be volatile.

This commentary originally appeared on Real Money Pro. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login